

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI

Charmacy Pharmaceutical Co., Ltd.

創美藥業股份有限公司

(A joint stock limited liability company established in the People's Republic of China)

(Stock Code: 2289)

POLL RESULTS OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING HELD ON 20 OCTOBER 2023

References are made to the announcement dated 20 September 2023, the notice of the 2023 second extraordinary general meeting dated 22 September 2023 (the “**Notice of EGM**”) and the circular dated 22 September 2023 (the “**Circular**”) of Charmacy Pharmaceutical Co., Ltd. (the “**Company**”). Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

POLL RESULTS OF THE EGM

The Board is pleased to announce that all the resolutions proposed as set out in the Notice of EGM were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of all the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the proposed amendments to the rules of procedures for shareholders' meetings of the Company (details of which are set out in the Circular) (please see Appendix II), and that any director of the Company (the “ Director(s) ”) be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the rules of procedures for shareholders' meetings of the Company.	90,743,500 (100%)	0 (0%)	0 (0%)

Ordinary Resolutions		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
2.	To consider and, if thought fit, approve the proposed amendments to the rules of procedures for board meetings of the Company (details of which are set out in the Circular) (please see Appendix III), and that any Director be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the rules of procedures for board meetings of the Company.	90,743,500 (100%)	0 (0%)	0 (0%)
Special Resolution		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
3.	To consider and, if thought fit, approve the proposed amendments to the articles of association of the Company (the “ Articles of Association ”) (details of which are set out in the Circular) (please see Appendix I), and that any Director be and is hereby authorised to modify the wordings of such amendments as appropriate (such amendments will not be required to be approved by the shareholders of the Company) and execute all such documents and/or do all such acts as the Directors may, in their absolute discretion, deem necessary or expedient and in the interest of the Company in order to deal with other related issues arising from the amendments to the Articles of Association.	90,743,500 (100%)	0 (0%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 2, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the resolution numbered 3, the resolution was duly passed as special resolution of the Company.

Notes:

1. As at the date of the EGM, the total number of issued Shares was 108,000,000 Shares, which represented the total number of Shares entitling the holders to attend and vote on the proposed resolutions at the EGM.
2. There were no Shares entitling the holders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM pursuant to Rule 13.40 of the Listing Rules, nor were there any Shareholders who were required under the Listing Rules to abstain from voting at the EGM.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM.
4. For the above resolutions, the Shareholders, proxies or authorised representatives holding in aggregate of 90,743,500 Shares, representing approximately 84.02% of the total voting Shares were present in person or by proxy at the EGM.

5. Pursuant to the Listing Rules, SHINEWING Certified Public Accountants (LLP), the auditors of the Company for the year 2023, was appointed as the scrutineer at the EGM for the purpose of vote-taking.
6. The attendance record of the Directors at the EGM was as follows:
Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi attended in person;
Mr. Yan Jingbin, Ms. Fu Zheng, Mr. Xu Fei, Mr. Wan Chi Wai Anthony and Mr. Li Hanguo attended by electronic means; and
Mr. Guan Jian was absent due to other engagements.

By order of the Board
Charmacy Pharmaceutical Co., Ltd.
Yan Jingbin
Chairman

Shantou, the PRC, 20 October 2023

As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive Directors are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Li Hanguo and Mr. Guan Jian (also known as Guan Suzhe).